Skip to search formSkip to main contentSkip to account menu

American Society of Clinical Oncology

Known as: ASCO 
The world's leading professional organization representing physicians of all oncology disciplines and subspecialties. ASCO sets the standard for… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
1. OVERVIEW: GENERAL PRINCIPLES FOR ALL ASCO GUIDELINE PRODUCTS ( e.g. de novo, Update, Endorsement, Adaptation, Provisional… 
Highly Cited
2014
Highly Cited
2014
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from…
1005 Background: We previously showed in participants with TNBC of the neoadjuvant phase II GeparSixto study (NCT01426880) that… 
Highly Cited
2010
Highly Cited
2010
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma…
4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate… 
Highly Cited
2009
Highly Cited
2009
First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537).
LBA6006 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings… 
Review
2006
Review
2006
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
LBA3 Background: Two multicenter phase II trials of 2nd line monotherapy with sunitinib (SU11248) in patients (pts) with mRCC… 
Highly Cited
2005
Highly Cited
2005
Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance…
7058 Background: Significant pneumonitis (≥ grade 3) is reported in up to 19% of patients (pts) with stage III non-small cell… 
Highly Cited
2004
Highly Cited
2004
A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity… 
2004
2004
Cancer prevention and the American Society of Clinical Oncology.
Scott M. Lippman and Bernard Levin, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Dean E. Brenner… 
Highly Cited
2004
Highly Cited
2004
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the…
4020 Background: ECF is currently considered by many as a standard regimen in AGC in Europe. Based on the high efficacy reported… 
Review
1996
Review
1996
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
PURPOSE Dissemination of use of the hematopoietic colony-stimulating factors (CSFs) is unprecedented in oncology, with almost all… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)